10 AI News and Ratings You Should Not Miss

7. Tempus AI, Inc. (NASDAQ:TEM)

Number of Hedge Fund Holders: 17

Tempus AI, Inc. (NASDAQ:TEM) provides healthcare technology solutions, including diagnostic testing, clinical trial matching, data analytics, and AI-driven platforms for healthcare and pharmaceutical industries.

On February 19, Tempus AI secured $300 million in additional debt financing from Ares Management’s Credit funds to support its acquisition of Ambry Genetics, finalized on February 3, 2025. It brings Ares’ total funding for Tempus to approximately $560 million since 2022. Tempus uses AI and data-driven technology to improve clinical care and research and the management emphasized that this investment will help drive innovation in precision medicine. The company views the funding as crucial for advancing its technological solutions and improving patient outcomes across oncology, cardiology, and other medical fields. Douglas Dieter, Dr.P.H., Partner in the Ares Credit Group commented:

“Over the last two years, we’ve been impressed by the Tempus team’s execution of its growth strategy and complementary acquisition of Ambry, and we look forward to further supporting their efforts in AI-enabled solutions that help advancements in medicine.”